Hixon Zuercher LLC lifted its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.3% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 36,556 shares of the company’s stock after buying an additional 116 shares during the period. Johnson & Johnson accounts for approximately 4.0% of Hixon Zuercher LLC’s portfolio, making the stock its 6th largest holding. Hixon Zuercher LLC’s holdings in Johnson & Johnson were worth $6,458,000 at the end of the most recent quarter.
A number of other large investors also recently bought and sold shares of JNJ. Glassy Mountain Advisors Inc. purchased a new position in Johnson & Johnson during the fourth quarter worth approximately $35,000. Retirement Financial Solutions LLC purchased a new position in Johnson & Johnson during the fourth quarter worth approximately $40,000. TD Capital Management LLC purchased a new position in Johnson & Johnson during the third quarter worth approximately $48,000. Iron Horse Wealth Management LLC raised its stake in Johnson & Johnson by 112.8% during the fourth quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock worth $53,000 after purchasing an additional 159 shares during the period. Finally, Cowa LLC acquired a new stake in shares of Johnson & Johnson in the third quarter worth $58,000. Hedge funds and other institutional investors own 67.94% of the company’s stock.
Wall Street Analyst Weigh In
Several research firms have recently issued reports on JNJ. Citigroup increased their price objective on shares of Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a research report on Monday, December 12th. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, February 1st. UBS Group began coverage on shares of Johnson & Johnson in a research report on Tuesday, March 28th. They issued a “neutral” rating and a $164.00 price objective for the company. Guggenheim began coverage on shares of Johnson & Johnson in a research report on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 price objective for the company. Finally, StockNews.com began coverage on shares of Johnson & Johnson in a research report on Thursday, March 16th. They issued a “strong-buy” rating for the company. Eight research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $173.67.
Johnson & Johnson Price Performance
Johnson & Johnson (NYSE:JNJ – Get Rating) last released its earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, topping the consensus estimate of $2.22 by $0.13. The company had revenue of $23.71 billion during the quarter, compared to the consensus estimate of $23.90 billion. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.76%. The company’s revenue was down 4.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.13 EPS. Equities analysts expect that Johnson & Johnson will post 10.5 EPS for the current fiscal year.
Johnson & Johnson Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st were issued a $1.13 dividend. This represents a $4.52 annualized dividend and a dividend yield of 2.92%. The ex-dividend date was Friday, February 17th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 67.06%.
Insider Activity
In other news, insider James D. Swanson sold 1,062 shares of Johnson & Johnson stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $154.66, for a total value of $164,248.92. Following the completion of the transaction, the insider now directly owns 9,215 shares of the company’s stock, valued at approximately $1,425,191.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.35% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Featured Articles
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- MarketBeat Week in Review – 3/27 – 3/31
- What is a Gold IRA, and is it a Viable Investment?
- Is Braze Inc Ready To Rocket Higher?
- Mullen Automotive Makes Deliveries; Short-Squeeze Possible
- Can Frontline Maintain This Momentum?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
